The change from a 510k back to its original De Novo pathway is mostly a non-event for the case. While it shifts the timeline slightly for an approval, we argue that it cements BONESUPPORT’s competitive (regulatory-wise) position, as it makes CERAMENT V the predicate device for future potential market entrants.
LÄS MER
